[go: up one dir, main page]

AR078253A1 - Metodos para reducir la actividad antivirica en composiciones pcv-2 y composiciones pcv-2 con mejor inmunogenicidad - Google Patents

Metodos para reducir la actividad antivirica en composiciones pcv-2 y composiciones pcv-2 con mejor inmunogenicidad

Info

Publication number
AR078253A1
AR078253A1 ARP100103209A ARP100103209A AR078253A1 AR 078253 A1 AR078253 A1 AR 078253A1 AR P100103209 A ARP100103209 A AR P100103209A AR P100103209 A ARP100103209 A AR P100103209A AR 078253 A1 AR078253 A1 AR 078253A1
Authority
AR
Argentina
Prior art keywords
pcv
antigen
compositions
immunogenic composition
methods
Prior art date
Application number
ARP100103209A
Other languages
English (en)
Inventor
Guosong Zhao
Ali Khazraeinazmpour
Bernd Eichenmueller
Marc Eichmeyer
Gregory Haiwick
Merrill Schaeffer
Caroline Kohler
Original Assignee
Boehringer Ingelheim Vetmed
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43016553&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR078253(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Vetmed filed Critical Boehringer Ingelheim Vetmed
Publication of AR078253A1 publication Critical patent/AR078253A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Métodos para reducir la actividad antivírica de una composicion que comprende un antígeno PCV-2 al igual que preparaciones antigénicas y composiciones inmunogénicas que comprenden un antígeno PCV-2, en donde se redujo la actividad antivirica. Además, un método para aumentar la inmunogenicidad de una composicion inmunogénica que comprende un antígeno PCV-2 y también una composicion inmunogénica con mayor inmunogenicidad. Reivindicacion 37: La composicion inmunogénica de acuerdo con la reivindicacion 35 o 36, caracterizada porque el antígeno de PCV-2 es una proteína del ORF2 recombinante de circovirus porcino que se expresa en bacterias o células animales. Reivindicacion 38: La composicion inmunogénica de acuerdo con cualquiera de las reivindicaciones 35 a 37, caracterizada porque la proteína del ORF2 de circovirus porcino se puede obtener mediante un proceso que comprende las siguientes etapas: a. expresar el antígeno de PCV-2 2 en una célula huésped; b. recolectar el cultivo celular para obtener el antígeno de PCV-2; c. purificar la recoleccion que comprende el antígeno PCV-2 mediante filtracion en gel; d. mezclar el antígeno de PCV-2 purificado con un adyuvante.
ARP100103209A 2009-09-02 2010-09-01 Metodos para reducir la actividad antivirica en composiciones pcv-2 y composiciones pcv-2 con mejor inmunogenicidad AR078253A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23919209P 2009-09-02 2009-09-02
US30940810P 2010-03-01 2010-03-01

Publications (1)

Publication Number Publication Date
AR078253A1 true AR078253A1 (es) 2011-10-26

Family

ID=43016553

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100103209A AR078253A1 (es) 2009-09-02 2010-09-01 Metodos para reducir la actividad antivirica en composiciones pcv-2 y composiciones pcv-2 con mejor inmunogenicidad

Country Status (20)

Country Link
US (1) US9561270B2 (es)
EP (1) EP2473189B1 (es)
JP (1) JP5921435B2 (es)
KR (1) KR101773754B1 (es)
CN (2) CN107412760A (es)
AR (1) AR078253A1 (es)
AU (1) AU2010289431B2 (es)
BR (1) BR112012004698B1 (es)
CA (1) CA2772928C (es)
CL (1) CL2012000562A1 (es)
CO (1) CO6511229A2 (es)
DK (1) DK2473189T3 (es)
ES (1) ES2657812T3 (es)
IN (1) IN2012DN01898A (es)
MX (1) MX340760B (es)
MY (1) MY165831A (es)
RU (1) RU2595395C2 (es)
SG (2) SG10201405406VA (es)
TW (1) TWI627281B (es)
WO (1) WO2011028888A2 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7833707B2 (en) 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
UA95602C2 (ru) 2004-12-30 2011-08-25 Берингер Ингельхейм Ветмедика, Инк. Иммуногенная композиция цвс2 и способы приготовления такой композиции
US8834891B2 (en) 2005-03-14 2014-09-16 Boehringer Ingelheim Vetmedica, Inc. Immunogenic compositions comprising Lawsonia intracellularis
SG170792A1 (en) 2005-12-29 2011-05-30 Boehringer Ingelheim Vetmed Use of a pcv2 immunogenic composition for lessening clinical symptoms in pigs
DK1968630T5 (en) 2005-12-29 2018-08-13 Boehringer Ingelheim Vetmedica Inc MULTIVALENT PCV2 IMMUNOGENIC COMPOSITIONS.
EP2101815A4 (en) 2006-12-11 2010-10-06 Boehringer Ingelheim Vetmed Effective method of treatment of porcine circovirus and lawsonia intracellularis infections
WO2008076915A2 (en) 2006-12-15 2008-06-26 Boehringer Ingelheim Vetmedica, Inc. Treatment of pigs with pcv2 antigen
EP1941903A1 (en) 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxis and treatment of PRDC
EP1958644A1 (en) 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prevention and treatment of sub-clinical pcvd
US7829274B2 (en) 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
CN101980720A (zh) 2008-01-23 2011-02-23 贝林格尔.英格海姆维特梅迪卡有限公司 Pcv2猪肺炎支原体致免疫组合物及其制备方法
AR078253A1 (es) 2009-09-02 2011-10-26 Boehringer Ingelheim Vetmed Metodos para reducir la actividad antivirica en composiciones pcv-2 y composiciones pcv-2 con mejor inmunogenicidad
CN103102397A (zh) * 2011-11-09 2013-05-15 韩健宝 预防和治疗pcv-2病毒的肽核酸及其制剂
WO2014179200A1 (en) * 2013-04-30 2014-11-06 Boehringer Ingelheim Vetmedica, Inc. Orf2 protein of pcv2 subtype a (pcv2a) for use in cross-protection
PL2994162T3 (pl) 2013-05-08 2021-10-18 Pharmgate Biologics Inc. Szczepionka przeciwko pcv2 i mykoplazmie
CN105658660A (zh) 2013-10-02 2016-06-08 勃林格殷格翰动物保健公司 Pcv2 orf2蛋白变体和由其组成的病毒样颗粒
CA3009656A1 (en) * 2015-12-28 2017-07-06 Merial, Inc. M hyo multivalent vaccine and uses thereof
JP6941171B2 (ja) * 2016-11-03 2021-09-29 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハーＢｏｅｈｒｉｎｇｅｒ Ｉｎｇｅｌｈｅｉｍ Ｖｅｔｍｅｄｉｃａ ＧｍｂＨ ブタパルボウイルスおよびブタ繁殖呼吸障害症候群ウイルスに対するワクチン、ならびにこれらを作製する方法
KR102905685B1 (ko) * 2018-03-26 2025-12-30 베링거 인겔하임 애니멀 헬스 유에스에이 인크. 면역원성 조성물의 제조방법
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
CN113957059B (zh) * 2021-11-26 2023-08-22 山东滨州沃华生物工程有限公司 一步柱层析工艺精纯猪蓝耳病毒的方法

Family Cites Families (213)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US3137631A (en) 1959-12-01 1964-06-16 Faberge Inc Encapsulation in natural products
US3080291A (en) 1960-06-10 1963-03-05 Jensen Salsberg Lab Inc Serial passage of distemper virus in tissue cultures of chick embryo and canine tissue and vaccine therefrom
US3959457A (en) 1970-06-05 1976-05-25 Temple University Microparticulate material and method of making such material
US4015100A (en) 1974-01-07 1977-03-29 Avco Everett Research Laboratory, Inc. Surface modification
US4122167A (en) 1977-02-09 1978-10-24 Merck & Co., Inc. Respiratory synctial vaccine
US4205060A (en) 1978-12-20 1980-05-27 Pennwalt Corporation Microcapsules containing medicament-polymer salt having a water-insoluble polymer sheath, their production and their use
US4224412A (en) 1979-05-01 1980-09-23 Dorofeev Viktor M Living virus culture vaccine against canine distemper and method of preparing same
US4769331A (en) 1981-09-16 1988-09-06 University Patents, Inc. Recombinant methods and materials
US4554159A (en) 1981-11-12 1985-11-19 Institute Merieux Vaccine and method of immunizing against herpes simplex virus (types 1 and 2)
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5364773A (en) 1991-03-07 1994-11-15 Virogenetics Corporation Genetically engineered vaccine strain
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4452747A (en) 1982-03-22 1984-06-05 Klaus Gersonde Method of and arrangement for producing lipid vesicles
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4468346A (en) 1983-10-27 1984-08-28 The United States Of America As Represented By The Secretary Of Agriculture Monoclonal antibodies to porcine immunoglobulins
DE3405100A1 (de) 1984-02-14 1985-08-14 Drägerwerk AG, 2400 Lübeck Pt-katalysator auf einem traeger als luftreinigungsmittel
US4744933A (en) 1984-02-15 1988-05-17 Massachusetts Institute Of Technology Process for encapsulation and encapsulated active material system
US5008050A (en) 1984-06-20 1991-04-16 The Liposome Company, Inc. Extrusion technique for producing unilamellar vesicles
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4921706A (en) 1984-11-20 1990-05-01 Massachusetts Institute Of Technology Unilamellar lipid vesicles and method for their formation
US4606940A (en) 1984-12-21 1986-08-19 The Ohio State University Research Foundation Small particle formation and encapsulation
US5206163A (en) 1985-07-08 1993-04-27 Chiron Corporation DNA encoding bovine diarrhea virus protein
ZA864879B (en) 1985-07-08 1987-03-25 Wallone Region Vaccines and diagnostics derived from boving diarrhoea virus
US4753884A (en) 1986-01-28 1988-06-28 Novagene, Inc. Pseudorabies virus mutants, vaccines containing same, methods for the production of same and methods for the use of same
JPS62198626A (ja) 1986-02-26 1987-09-02 Biseibutsu Kagaku Kenkyusho:Kk 血球凝集性脳脊髄炎ウイルス感染症予防ワクチン
FR2602791B1 (fr) 1986-08-18 1988-11-10 Ministere Agri Direction Quali Procede de culture du virus de la rhinotracheite infectieuse de la dinde, et vaccin prepare a partir du virus ainsi obtenu
IL84154A0 (en) 1986-10-16 1988-03-31 Microgenesys Inc Polypeptides derived from the envelope gene of human immunodeficiency virus in recombinant baculovirus infected insect cells and vaccines against acquired immune deficiency syndrome containing the same
NZ222465A (en) 1986-11-07 1992-11-25 Pasteur Institut Nanb (non a, non b hepatitis viral) antigen
US5009956A (en) 1987-02-24 1991-04-23 Univ Minnesota Phospholipase A2-resistant liposomes
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5069901A (en) 1988-02-03 1991-12-03 Jones Elaine V Preparation of a recombinant subunit vaccine against pseudorabies infection
DE3833925A1 (de) 1988-03-11 1989-09-21 Inst Angewandte Biotechnologie Verfahren und herstellung von virus und viralem antigen und vorrichtung hierzu
US5213759A (en) 1988-05-05 1993-05-25 Elopak Systems A.G. Sterilization
WO1990001543A1 (fr) 1988-07-29 1990-02-22 Intracel Corporation Procede d'expression genetique de proteines heterologues par des cellules transfectees in vivo
CA2003300A1 (en) 1988-11-21 1990-05-21 Franklin Volvovitz Skin test and test kit for aids
US4927637A (en) 1989-01-17 1990-05-22 Liposome Technology, Inc. Liposome extrusion method
AU638970B2 (en) 1989-01-23 1993-07-15 Auspharm International Limited Vaccine composition
US4944948A (en) 1989-02-24 1990-07-31 Liposome Technology, Inc. EGF/Liposome gel composition and method
DE69034078T2 (de) 1989-03-21 2004-04-01 Vical, Inc., San Diego Expression von exogenen Polynukleotidsequenzen in Wirbeltieren
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5591439A (en) 1989-03-24 1997-01-07 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
US5552143A (en) 1989-03-24 1996-09-03 The Wistar Institute Of Anatomy & Biology Recombinant cytomegalovirus vaccine
US5202130A (en) * 1989-08-31 1993-04-13 The Johns Hopkins University Suppression of eczematous dermatitis by calcium transport inhibition
US5132117A (en) 1990-01-11 1992-07-21 Temple University Aqueous core microcapsules and method for their preparation
US5202430A (en) 1990-01-16 1993-04-13 University Of Tennessee Transmissible gastroenteritis virus genes
GB9001766D0 (en) 1990-01-25 1990-03-28 Univ Court Of The University O Vaccines
AU7007491A (en) 1990-02-02 1991-08-08 Schweiz. Serum- & Impfinstitut Bern Cdna corresponding to the genome of negative-strand rna viruses, and process for the production of infectious negative-strand rna viruses
ES2112274T5 (es) 1990-05-29 2006-03-01 Wyeth Holdings Corporation Vacuna contra la pneumonia en cerdos y metodo para la preparacion de la misma.
US5565205A (en) 1990-08-16 1996-10-15 Solvay Animal Health, Inc. Inactivated Mycoplasma hypopneumoniae bacterin and method of use thereof
GB9023111D0 (en) 1990-10-24 1990-12-05 Wellcome Found Expression system
CA2094515C (en) 1990-11-01 1998-09-01 Theodore T. Kramer Bacterial attenuation method and vaccine
KR100242671B1 (ko) 1991-03-07 2000-03-02 고돈 에릭 유전학적으로 처리한 백신 균주
US5997878A (en) 1991-03-07 1999-12-07 Connaught Laboratories Recombinant poxvirus-cytomegalovirus, compositions and uses
EP0587780B2 (en) 1991-06-06 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Causative agent of the mystery swine disease, vaccine compositions and diagnostic kits
US5846805A (en) 1991-08-26 1998-12-08 Boehringer Ingelheim Animal Health, Inc. Culture of swine infertility and respiratory syndrome virus in simian cells
EP0601062B2 (en) 1991-08-26 2000-12-13 Regents Of The University Of Minnesota Sirs vaccine and diagnosis method
MX9204885A (es) 1991-08-26 1994-05-31 Boehringer Animal Health Inc Composicion de vacuna que comprende virus del sindrome de infertilidad y respiratorio de los cerdos.
US6080570A (en) 1991-08-26 2000-06-27 Boehringer Ingelheim Vetmedica, Inc. Method of producing a vaccine for Swine Infertility and Respiratory Syndrome
US6042830A (en) 1992-08-05 2000-03-28 Boehringer Ingelheim Vetmedica, Inc. Viral agent associated with mystery swine disease
US6982160B2 (en) 1991-08-26 2006-01-03 Boehringer Ingelheim Vetmedica, Inc. Immunogenic compositions that include SIRS virus
AU2696792A (en) 1991-09-16 1993-04-27 David A Benfield Vaccine for mystery swine disease and method for diagnosis thereof
US5580557A (en) 1991-10-09 1996-12-03 Iowa State University Research Foundation, Inc. Live, avirulent salmonella choleraesuis vaccine used for inducing an immune response in animals
CA2121241C (en) 1991-10-14 2007-12-04 Nicolaas Visser Porcine reproductive respiratory syndrome vaccine and diagnostic
US5382425A (en) 1992-01-13 1995-01-17 Syntro Corporation Recombinant swinepox virus
FR2686097B1 (fr) 1992-01-14 1994-12-30 Rhone Merieux Preparation d'antigenes et de vaccins de virus de la mystery disease, antigenes et vaccins obtenus pour la prevention de cette maladie.
US5338543A (en) 1992-02-27 1994-08-16 Ambico, Inc. Thimerosal inactivated mycoplasma hyopneumoniae vaccine
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
TW289731B (es) 1992-07-09 1996-11-01 Akzo Nv
US6773908B1 (en) 1992-10-30 2004-08-10 Iowa State University Research Foundation, Inc. Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (PRRSV)
US6251397B1 (en) 1992-10-30 2001-06-26 Iowa State University Research Foundation, Inc. Proteins encoded by polynucleic acids isolated from a porcine reproductive and respiratory syndrome virus and immunogenic compositions containing the same
US5695766A (en) 1992-10-30 1997-12-09 Iowa State University Research Foundation Highly virulent porcine reproductive and respiratory syndrome viruses which produce lesions in pigs and vaccines that protect pigs against said syndrome
US6592873B1 (en) 1992-10-30 2003-07-15 Iowa State University Research Foundation, Inc. Polynucleic acids isolated from a porcine reproductive and respiratory syndrome virus (PRRSV) and proteins encoded by the polynucleic acids
US6380376B1 (en) 1992-10-30 2002-04-30 Iowa State University Research Foundation Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (PRRSV)
US5419907A (en) 1992-11-10 1995-05-30 Iowa State University Research Foundation, Inc. Pathogenic porcine respiratory coronavirus
EP0683816B1 (en) 1993-02-08 2000-11-02 Bayer Corporation Process for growing porcine reproductive and respiratory syndrome virus and its use in vaccines
US5801029A (en) 1993-02-16 1998-09-01 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
IL108915A0 (en) 1993-03-18 1994-06-24 Merck & Co Inc Polynucleotide vaccine against influenza virus
ES2074950B1 (es) 1993-09-17 1996-03-16 Iberica Cyanamid Vacuna para la prevencion de la enfermedad reproductiva y respiratoria de la cerda.
FR2711670B1 (fr) 1993-10-22 1996-01-12 Pasteur Institut Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
EP0659885A1 (en) 1993-12-21 1995-06-28 Akzo Nobel N.V. Vaccine against viruses associated with antibody-dependent-enhancement of viral infectivity
ATE475668T1 (de) 1994-01-27 2010-08-15 Univ Massachusetts Medical Immunisierung durch impfung von dns transkriptionseinheit
DE4407489A1 (de) 1994-03-07 1995-09-14 Bayer Ag Vakzine zur Prävention von Respirations- und Reproduktionserkrankungen des Schweines
HRP950097A2 (en) 1994-03-08 1997-06-30 Merck & Co Inc Hepatitis a virus culture process
EP0676467B1 (en) 1994-04-11 2001-10-04 Akzo Nobel N.V. European vaccine strains of the porcine reproductive respiratory syndrome virus (PRRSV)
ATE235959T1 (de) 1994-04-15 2003-04-15 Univ Temple Methode zum einkapseln mittels eines wässrigen lösungsmittels und mikrokapseln
JP3911010B2 (ja) 1994-04-29 2007-05-09 イムノ・アクテイエンゲゼルシヤフト 必須領域に外来ポリヌクレオチドを有する組換えポックスウイルス
NZ285324A (en) 1994-05-10 1998-08-26 American Home Prod Vaccine containing modified live bovine respiratory syncytial virus (brsv) with an adjuvant and pharmaceutically acceptable carrier
DK53595A (da) 1994-05-13 1995-11-14 Iberica Cyanamid Rekombinante PRRSV-proteiner, diagnostiske kits og vaccine indeholdende sådanne rekombinante PRRSV-proteiner
PT783321E (pt) 1994-08-05 2006-08-31 Univ Minnesota Sequencia nucleotidica viral vr-2332 e metodos de utilizacao
DE69632658T2 (de) 1995-03-14 2005-06-09 Akzo Nobel N.V. Expression in der selben Zelle von Polypeptide vom schweinen reproduktiven und respiratorischen Syndrom
JPH11502222A (ja) 1995-03-23 1999-02-23 キャンタブ ファーマシューティカルズ リサーチ リミティド 遺伝子供給用ベクター
US5885823A (en) 1995-06-05 1999-03-23 Nobl Laboratories, Inc. Lawsonia intracellularis cultivation, anti-Lawsonia intracellularis vaccines and diagnostic agents
US5690940A (en) 1995-06-21 1997-11-25 Regents Of The University Of Minnesota Low pathogencity PRRS live virus vaccines and methods of preparation thereof
NZ315357A (en) 1995-08-01 1999-08-30 Pasteur Merieux Serums Vacc Method for industrially producing a japanese encephalitis vaccine, and resulting vaccine
ES2102971B1 (es) 1996-01-25 1998-03-01 Hipra Lab Sa Nueva cepa atenuada del virus causante del sindrome respiratorio y reproductivo porcino (prrs), las vacunas y medios de diagnostico obtenibles con la misma y los procedimientos para su obtencion.
US5866401A (en) 1996-03-01 1999-02-02 Schering Corporation Porcine reproductive and respiratory syndrome vaccine
US6015663A (en) 1996-03-01 2000-01-18 The United States Of America As Represented By The Secretary Of Agriculture Restriction enzyme screen for differentiating porcine reproductive and respiratory syndrome virus strains
CA2248182C (en) 1996-03-01 2004-04-20 Schering Corporation Porcine reproductive and respiratory syndrome vaccine
US5976537A (en) 1996-07-02 1999-11-02 The United States Of America As Represented By The Secretary Of Agriculture Porcine reproductive and respiratory syndrome vaccine
WO1998000166A1 (en) 1996-07-03 1998-01-08 Merial, Inc. Recombinant canine adenovirus (cav) containing exogenous dna
ATE199022T1 (de) 1996-10-09 2001-02-15 Akzo Nobel Nv Europäische vakzinstämme des fortplanzungs- atmungs-syndromsvirus des sweins (prrsv)
US20040224327A1 (en) 1996-10-30 2004-11-11 Meulenberg Johanna Jacoba Maria Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof
EP0839912A1 (en) 1996-10-30 1998-05-06 Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof
US6183752B1 (en) 1997-02-05 2001-02-06 Pasteur Merieux Serums Et Vaccins Restenosis/atherosclerosis diagnosis, prophylaxis and therapy
WO1998035023A1 (en) 1997-02-07 1998-08-13 Origen, Inc. Method for growing porcine reproductive and respiratory syndrome virus for use as vaccines and diagnostic assays
PT980387E (pt) 1997-05-06 2007-07-31 Boehringer Ingelheim Vetmed Sítios antigénicos de prrsv que identificam sequências peptídicas do vírus prrsv para utilização em vacinas ou em ensaios de diagnóstico
WO1998055625A1 (en) 1997-06-04 1998-12-10 Calgene, Llc Production of polyunsaturated fatty acids by expression of polyketide-like synthesis genes in plants
AU7960598A (en) 1997-06-05 1998-12-21 Origen, Inc. Recombinant porcine reproductive and respiratory syndrome virus (prrsv) for use as a vaccine
US20060029617A1 (en) 1997-10-03 2006-02-09 Charreyre Catherine E Porcine circovirus and Helicobacter combination vaccines and methods of use
US6391314B1 (en) 1997-10-03 2002-05-21 Merial Porcine circoviruses vaccines diagnostic reagents
UA78180C2 (uk) 1997-10-03 2007-03-15 Меріаль Кільцевий вірус свині типу ii, вакцини та діагностичні реагенти
US7192594B2 (en) 1997-10-03 2007-03-20 Merial Limited Postweaning multisystemic wasting syndrome and porcine circovirus from pigs
US7211379B2 (en) 1997-10-03 2007-05-01 Merial Sas Prevention of myocarditis, abortion and intrauterine infection associated with porcine circovirus-2
US6517843B1 (en) 1999-08-31 2003-02-11 Merial Reduction of porcine circovirus-2 viral load with inactivated PCV-2
FR2781159B1 (fr) * 1998-07-06 2000-10-06 Merial Sas Vaccin circovirus et parvovirus porcin
US20040062775A1 (en) 1997-12-05 2004-04-01 Agence Francaise De Securite Sanitaire Des Aliments Circovirus sequences associated with piglet weight loss disease (PWD)
FR2772047B1 (fr) 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
CA2313806A1 (en) 1997-12-11 1999-06-17 University Of Saskatchewan Postweaning multisystemic wasting syndrome virus from pigs
US6287856B1 (en) 1998-03-13 2001-09-11 University Of Georgia Research Foundation, Inc. Vaccines against circovirus infections
US6294176B1 (en) 1998-07-10 2001-09-25 Schering-Plough Veterinary Corp. Recombinant raccoonpox virus and uses thereof as a vaccine in mammalian and avian species
EP1050584B1 (en) 1998-11-19 2006-10-18 Azwell Inc. Recombinant lysophosphatidic acid phosphatase
US7132106B2 (en) 1998-12-22 2006-11-07 Pfizer Inc. Infectious cDNA clone of North American porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof
US7618797B2 (en) 1998-12-22 2009-11-17 Pfizer Inc Infectious cDNA clone of North American porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof
NZ513289A (en) 1998-12-22 2003-04-29 Pfizer Prod Inc Infectious cDNA clone of north american procine reproductive and respiratory syndrome (PRRS) virus and uses thereof
US7691389B2 (en) 1998-12-22 2010-04-06 Pfizer Inc Infectious cDNA clone of north american porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof
FR2789695B1 (fr) 1999-02-11 2003-03-07 Merial Sas Vecteurs et vaccins viraux a base d'adenovirus porcins recombines et replicatifs
JP3961222B2 (ja) 1999-03-08 2007-08-22 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー Ｐｒｒｓｖワクチン
MXPA01010681A (es) 1999-04-22 2003-08-20 Us Agriculture Vacuna de sindrome respiratorio y reproductiva porcina a base de ja-142 aislado.
US6497883B1 (en) 1999-06-10 2002-12-24 Merial Porcine circovirus recombinant poxvirus vaccine
US6943152B1 (en) 1999-06-10 2005-09-13 Merial DNA vaccine-PCV
GB9921146D0 (en) 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
WO2001017556A1 (fr) 1999-09-07 2001-03-15 Shionogi & Co., Ltd. Préparations vaccinales administrables par les muqueuses
GB9921147D0 (en) 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
US20040213805A1 (en) 1999-10-12 2004-10-28 Verheije Monique Helene Deletions in arterivirus replicons
WO2002095040A1 (en) 2001-05-21 2002-11-28 Id-Lelystad, Instituut Voor Dierhouderij En Diergezondheid B.V. Delections in arterivirus replicons
US6656478B1 (en) 1999-11-12 2003-12-02 Samuel D. Charles Cross-protective salmonella vaccines
PT1248646E (pt) 1999-12-21 2008-03-19 Merial Sas Composições e vacinas contendo antigénio(s) de cryptosporidium parvum e de outro patógeno entérico
US20020012670A1 (en) 2000-01-26 2002-01-31 Knut Elbers Recombinant attenuation of porcine reproductive and respiratory syndrome (PRRSV)
EP1255815B1 (en) 2000-02-08 2006-07-19 Regents Of The University Of Minnesota Porcine reproductive and respiratory syndrome virus and methods of use
EP1156111A1 (en) 2000-05-19 2001-11-21 Stichting Dienst Landbouwkundig Onderzoek Chimeric arterivirus-like particles
JP2004503234A (ja) 2000-06-15 2004-02-05 パーデュー・リサーチ・ファウンデーション ブタの先天性振せん用ワクチン
US6808900B2 (en) 2000-06-15 2004-10-26 Manitoba, University Of Cryptosporidium parvum antigens, antibodies thereto and diagnostic and therapeutic compositions thereof
WO2002060921A2 (en) 2000-11-09 2002-08-08 Board Of Trustees Of The University Of Illinois Enhancement of immune response to vaccine by interferon alpha
MY129765A (en) 2000-12-19 2007-04-30 Wyeth Corp Improved mycoplasma hyopneumoniae bacterin vaccine
US7018638B2 (en) 2000-12-19 2006-03-28 Wyeth Mycoplasma hyopneumoniae bacterin vaccine
JP2002247979A (ja) 2001-02-23 2002-09-03 Nippon Biologicals Inc マレック病ワクチンおよびその製造方法
CZ304525B6 (cs) 2001-03-27 2014-06-18 University Of Saskatchewan Způsob kultivace circoviru
US20030096377A1 (en) 2001-06-28 2003-05-22 Virginia Tech Intellectual Properties, Inc. Differential PCR-RFLP assay for detecting and distinguishing between nonpathogenic PCV-1 and pathogenic PCV-2
PT1474067E (pt) 2001-07-02 2008-11-14 Pfizer Prod Inc Vacinação numa dose com mycoplasma hyopneumoniae
US7361352B2 (en) 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
US7276353B2 (en) 2001-12-12 2007-10-02 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
US7279166B2 (en) 2001-12-12 2007-10-09 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
US6841364B2 (en) 2002-01-22 2005-01-11 Protatek International, Inc. Infectious cDNA clones of porcine reproductive and respiratory syndrome virus and expression vectors thereof
WO2003077860A2 (en) 2002-03-13 2003-09-25 Biophysica, Inc. BOSWELLIN COMPOSITIONS ENHANCED WITH 3-β-ACETYL-11-KETO-β-BOSWELLIC ACID (“AKBA”), INDUSTRIAL MANUFACTURE AND THEIR USES
ATE557082T1 (de) 2002-04-05 2012-05-15 Boehringer Ingelheim Vetmed Sequenz positionen zur anpassung bei prrsv
US20030215455A1 (en) 2002-05-14 2003-11-20 Bailey Reynolds Vaccine stabilizer and method of use
AU2002951692A0 (en) 2002-09-23 2002-10-17 Vital Biotech (Hong Kong) Limited Improvements in or relating to vaccines
EP1599164B1 (en) 2003-02-03 2015-04-08 Cerebus Biologicals, Inc. Methods for treating, preventing and detecting helicobacter infection
US7563449B2 (en) 2003-04-21 2009-07-21 Pfizer Inc, Methods for reducing cattle reproductive diseases
CN1458167A (zh) 2003-06-02 2003-11-26 中国农业科学院哈尔滨兽医研究所 截短表达的猪圆环病毒ⅱ型衣壳蛋白抗原及其应用
US7335361B2 (en) 2003-06-09 2008-02-26 Animal Technology Institute Taiwan Fusion antigen used as vaccine
AU2004259034C1 (en) 2003-07-24 2010-12-16 Boehringer Ingelheim Animal Health USA Inc. Vaccine formulations comprising an oil-in-water emulsion
US7312065B2 (en) 2003-07-25 2007-12-25 Boehringer Ingelheim Vetmedica, Inc. Lawsonia intracellularis of European origin and vaccines, diagnostic agents and methods of use thereof
FR2861731B1 (fr) 2003-10-30 2006-02-24 Centre Nat Rech Scient Nouvelle proteine de fixation du phosphate, compositions pharmaceutiques la contenant et ses utilisations
WO2005112995A1 (en) 2004-04-26 2005-12-01 Choongang Vaccine Laboratory Co., Ltd. Inactivated mixed vaccine for porcine respiratory disease and the method of manufacturing thereof
CN1579553A (zh) 2004-05-18 2005-02-16 浙江大学 Ii型猪圆环病毒核酸疫苗的制备方法及其应用
US7722878B2 (en) 2004-06-17 2010-05-25 Boehringer Ingelheim Vetmedica, Inc. PRRSV subunit vaccines
KR20070028547A (ko) 2004-06-18 2007-03-12 리전츠 오브 더 유니버스티 오브 미네소타 바이러스에 감염되고 백신접종된 생물의 동정
AU2005319716A1 (en) 2004-06-30 2006-06-29 Id Biomedical Corporation Of Quebec Vaccine compositions for treating coronavirus infection
US7632636B2 (en) 2004-09-21 2009-12-15 Boehringer Ingelheim Vetmedica, Inc. Porcine reproductive and respiratory syndrome isolates and methods of use
US20060063151A1 (en) 2004-09-21 2006-03-23 Michael Roof Porcine reproductive and respiratory syndrome isolates and methods of use
US7833707B2 (en) 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
US7700285B1 (en) * 2005-12-29 2010-04-20 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
KR20070096019A (ko) 2005-01-13 2007-10-01 베링거잉겔하임베트메디카게엠베하 향상된 ｐｒｒｓ 백신
US7300785B2 (en) 2005-02-03 2007-11-27 Universiteit Ghent Culturing circular ssDNA viruses for the production of vaccines
US8834891B2 (en) 2005-03-14 2014-09-16 Boehringer Ingelheim Vetmedica, Inc. Immunogenic compositions comprising Lawsonia intracellularis
WO2006113435A2 (en) 2005-04-13 2006-10-26 Merial Limited Method for porcine circovirus production and assays for monitoring production
US7691368B2 (en) 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
SI1904631T1 (sl) 2005-06-24 2012-09-28 Univ Minnesota Virusi PRRS, infekciozni kloni, njihovi mutanti in postopki uporabe
BRPI0615862A2 (pt) 2005-09-09 2011-05-31 Intervet Int Bv vacina contra pcv-2, e, método para a manufatura de uma vacina
CN103641920B (zh) 2005-11-29 2016-08-17 衣阿华州立大学研究基金公司 猪繁殖与呼吸综合征病毒(prrsv)的保护性抗原决定子的鉴定及其用途
SG170792A1 (en) 2005-12-29 2011-05-30 Boehringer Ingelheim Vetmed Use of a pcv2 immunogenic composition for lessening clinical symptoms in pigs
DK1968630T5 (en) * 2005-12-29 2018-08-13 Boehringer Ingelheim Vetmedica Inc MULTIVALENT PCV2 IMMUNOGENIC COMPOSITIONS.
EP2099927A4 (en) 2006-11-22 2010-05-05 Boehringer Ingelheim Vetmed Methods of reducing porcine circovirus-associated disease outbreaks
EP2101815A4 (en) 2006-12-11 2010-10-06 Boehringer Ingelheim Vetmed Effective method of treatment of porcine circovirus and lawsonia intracellularis infections
WO2008073490A1 (en) * 2006-12-12 2008-06-19 Carrington Laboratories Inc., Purification of influenza viral antigens
WO2008076915A2 (en) 2006-12-15 2008-06-26 Boehringer Ingelheim Vetmedica, Inc. Treatment of pigs with pcv2 antigen
EP1941903A1 (en) * 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxis and treatment of PRDC
US8563313B2 (en) 2007-02-13 2013-10-22 Washington State University Research Foundation Macrophage cell-lines for propagation of porcine reproductive and respiratory syndrome virus
EP1958644A1 (en) 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prevention and treatment of sub-clinical pcvd
WO2008121958A1 (en) 2007-04-02 2008-10-09 Boehringer Ingelheim Vetmedica, Inc. Use of prrsv vaccines to reduce pcv2 viremia
GB0712160D0 (en) * 2007-06-22 2007-08-01 Univ Ghent Methods and compositions in the treatment of procine circoviral infection
US20090017064A1 (en) 2007-07-10 2009-01-15 Wyeth Methods and Compositions for Immunizing Pigs Against Porcine Circovirus
US7829274B2 (en) 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
WO2009085912A1 (en) 2007-12-21 2009-07-09 Wyeth Methods and compositions for immunizing pigs against porcine circovirus
CN101980720A (zh) * 2008-01-23 2011-02-23 贝林格尔.英格海姆维特梅迪卡有限公司 Pcv2猪肺炎支原体致免疫组合物及其制备方法
US20110033495A1 (en) 2008-02-15 2011-02-10 Boehringer Ingelheim Vetmedica, Inc. Methods and compositions for reducing the impact of enteric diseases
MX2010011353A (es) 2008-04-16 2011-02-23 Virginia Tech Intell Prop Circovirus porcino quimerico pcv2gen-1rep y usos del mismo.
TWI449533B (zh) 2008-04-18 2014-08-21 Intervet Int Bv 防備胞內勞森菌（Ｌａｗｓｏｎｉａ ｉｎｔｒａｃｅｌｌｕｌａｒｉｓ）、豬肺炎黴漿菌（Ｍｙｃｏｐｌａｓｍａ ｈｙｏｐｎｅｕｍｏｎｉａｅ）及豬環狀病毒（Ｐｏｒｃｉｎｅ ｃｉｒｃｏ ｖｉｒｕｓ）用疫苗
US8444989B1 (en) 2008-04-18 2013-05-21 Boehringer Ingelheim Vetmedica Gmbh One dose vaccination against mycoplasma infections of pigs
US20100003278A1 (en) 2008-07-03 2010-01-07 Boehringer Ingelheim Vetmedica, Inc. Immunological Compositions Effective for Lessening the Severity or Incidence of PRRSV Signs and Methods of Use Thereof
BRPI0917887A2 (pt) 2008-08-25 2019-09-03 Boehringer Ingelheim Vetmedica Inc vacina contra síndrome reprodutiva e respiratória suína altamente patogênica (hp pprs)
US20100129398A1 (en) 2008-11-26 2010-05-27 Boehringer Ingelheim Vetmedica, Inc. Materials and Methods for Control of Porcine Reproductive and Respiratory Syndrome
AR078253A1 (es) 2009-09-02 2011-10-26 Boehringer Ingelheim Vetmed Metodos para reducir la actividad antivirica en composiciones pcv-2 y composiciones pcv-2 con mejor inmunogenicidad
EP2558118B1 (en) 2010-04-16 2019-06-05 Universiteit Gent Cross-protecting vaccine for porcine reproductive and respiratory syndrome virus
US8728487B2 (en) 2011-01-20 2014-05-20 Hua Wu Attenuated live vaccine for prevention of porcine reproductive and respiratory syndrome
US8906385B2 (en) 2011-12-01 2014-12-09 University Of Maryland, College Park Interferon-inducing porcine reproductive and respiratory syndrome virus isolate

Also Published As

Publication number Publication date
WO2011028888A3 (en) 2011-06-23
MY165831A (en) 2018-05-17
US9561270B2 (en) 2017-02-07
TW201120212A (en) 2011-06-16
AU2010289431A1 (en) 2012-03-08
RU2012112636A (ru) 2013-10-27
CA2772928A1 (en) 2011-03-10
EP2473189B1 (en) 2017-11-15
SG10201405406VA (en) 2014-10-30
MX2012002329A (es) 2012-04-10
JP2013503893A (ja) 2013-02-04
MX340760B (es) 2016-07-21
KR20120104514A (ko) 2012-09-21
BR112012004698B1 (pt) 2022-03-08
AU2010289431B2 (en) 2017-02-02
CL2012000562A1 (es) 2012-10-12
IN2012DN01898A (es) 2015-07-24
CN102573899A (zh) 2012-07-11
RU2595395C2 (ru) 2016-08-27
BR112012004698A2 (pt) 2016-11-29
CO6511229A2 (es) 2012-08-31
CA2772928C (en) 2019-01-08
DK2473189T3 (da) 2018-01-29
TWI627281B (zh) 2018-06-21
JP5921435B2 (ja) 2016-05-24
CN107412760A (zh) 2017-12-01
EP2473189A2 (en) 2012-07-11
US20110059126A1 (en) 2011-03-10
KR101773754B1 (ko) 2017-09-01
SG178595A1 (en) 2012-04-27
ES2657812T3 (es) 2018-03-07
WO2011028888A2 (en) 2011-03-10

Similar Documents

Publication Publication Date Title
AR078253A1 (es) Metodos para reducir la actividad antivirica en composiciones pcv-2 y composiciones pcv-2 con mejor inmunogenicidad
BR112013032659A2 (pt) método para o tratamento de células-tronco mesenquimais, que compreende a obtenção e o isolamento das células-tronco mesenquimais e a cultura das células em um meio de tratamento; células-tronco mesenquimais; e uso das células
MX2019002495A (es) Metodos para producir virus para la produccion de vacunas.
RU2015137703A (ru) Линии клеток для получения вирусов и способы их применения
GB0916370D0 (en) Compositions
EA200801221A1 (ru) Вирусные вакцины, полученные из клеток, с низкими уровнями остаточной клеточной днк
PE20140222A1 (es) Vacunas basadas en omv contra infecciones por burkholderia
NZ611531A (en) Bovine viral diarrhea virus type 1b vaccine compositions and methods
MY170013A (en) Methods and compositions for enhancing stem cell mobilization
RU2009128650A (ru) Средство для роста фибробластов
EA201100862A1 (ru) Новый изолят свиного цирковируса типа 2b и его применения
MX2009007354A (es) Proceso para producir biomasa y proteinas mediante microalgas.
AR094389A1 (es) USO DE INHIBIDORES DE iNOS PARA AUMENTAR EL RENDIMIENTO VÍRICO EN CULTIVOS
PA8813901A1 (es) Paramixovirus oncolíticos atenuados que codifican citoquinas de aves
AR082374A1 (es) Proceso de fermentacion para streptococcus pneumoniae
ES2351296B8 (es) Cepas de s. cerevisiae capaces de crecer en medios con melibiosa, estaquiosa y rafinosa.
BR112015015107A2 (pt) método para remover contaminantes bacterianos de solução sacarificada e sistema de fermentação
CN102766595B (zh) 一种鱇浪白鱼心脏细胞系的构建方法
AR085271A1 (es) Procedimiento para la produccion a escala comercial de prrsv
BRPI0914805B8 (pt) método para replicar vírus em uma cultura de células scldk, processo para adaptar células cldk dependentes do substrato para desenvolvimento em suspensão, método para propagar continuamente células scldk em suspensão, e, composição
EA201000377A1 (ru) Способ получения фибробластоподобных клеток из пупочного канатика новорожденного
MX361186B (es) Metodo de alta eficiencia para purificar particulas similares a virus del virus del papiloma humano.
WO2019190175A3 (ko) 편도 유래 중간엽 줄기세포로부터 운동신경세포의 분화방법
ES2571241T3 (es) Procedimiento para preparar suspensiones de celulas humanas desinfectadas
Bertoni et al. Bilayered scaffolds colonized with dental pulp stem cells for osteochondral tissue engineering application

Legal Events

Date Code Title Description
FC Refusal